Sodium glucose co-transporter-2 (SGLT2) inhibitors – Safety update
March 17, 2020 - The FDA announced that they approved safety labeling changes for the SGLT2 inhibitors canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin regarding the temporary discontinuation of these medications before scheduled surgery.
Top